Oramed Pharmaceuticals Inc. cash flow to debt ratio of -1.11K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Oramed Pharmaceuticals Inc.'s free cash flow has decreased 31.41% from $-8.43M last year to $-11.08M, signaling decreasing performance

Oramed Pharmaceuticals Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Oramed Pharmaceuticals Inc.'s debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials

Oramed Pharmaceuticals Inc. has a net cash position, so leverage is healthy.

Oramed Pharmaceuticals Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Oramed Pharmaceuticals Inc. has insufficient data to evaluate this check.

Oramed Pharmaceuticals Inc.'s short-term assets of $133.27M exceed its short-term liabilities of $19.09M

Oramed Pharmaceuticals Inc.'s return on assets of 62.71% is higher than the 5.00% threshold, indicating efficient asset utilization

Oramed Pharmaceuticals Inc.'s return on equity of 82.73%, is higher than 15.00%, indicating good performance

Oramed Pharmaceuticals Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Oramed Pharmaceuticals Inc. had positive net income in only 2 out of 5 years, indicating unstable earnings

Oramed Pharmaceuticals Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Oramed Pharmaceuticals Inc. has negative free cash flow, indicating cash burn

Oramed Pharmaceuticals Inc.'s yearly earnings has increased -435.29% since last year from $-19.10M to $64.05M, signaling increasing performance

Oramed Pharmaceuticals Inc.'s yearly revenue has increased % since last year from $0.00 to $2.00M, signaling increasing performance

ROIC -3.46% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Oramed Pharmaceuticals Inc.'s 3-year revenue CAGR of -9.55% is negative, indicating declining revenue over the past 3 years

Oramed Pharmaceuticals Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Oramed Pharmaceuticals Inc. had positive ROE in only 2 out of 5 years, indicating inconsistent returns on equity

Oramed Pharmaceuticals Inc. has insufficient data to evaluate this check.

Oramed Pharmaceuticals Inc. has an earnings yield of 115.04%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Oramed Pharmaceuticals Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Oramed Pharmaceuticals Inc. has an EV/EBITDA ratio of 0.62x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Oramed Pharmaceuticals Inc. is overvalued relative to its fair value price of -3.28 based on Earnings Fair Value model

Oramed Pharmaceuticals Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Oramed Pharmaceuticals Inc. has a price-to-book ratio of 0.63x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Oramed Pharmaceuticals Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue